(Reuters) - Merck ( MRK ) and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr, the company said.

Merck ( MRK ) and the plaintiff plan to reconvene in a Los Angeles state court in September with a new jury, the company said in a statement provided to Reuters.

Kennedy, confirmed as HHS secretary last week, played an instrumental role in organizing mass litigation against Merck ( MRK ) over Gardasil before taking office, but has not been involved in the Los Angeles trial after entering an initial court appearance in the case. He did not immediately respond to a request for comment.

On Friday, following four weeks of trial, plaintiffs' lawyers approached Merck ( MRK ) and proposed the jury be discharged and the case adjourned, the company said. Merck ( MRK ) agreed "subject to an explicit stipulation that Merck ( MRK ) would provide no financial or other consideration in exchange for the agreement to adjourn," the company said.

The plaintiff in the case, Jennifer Robi, 30, was vaccinated with Gardasil as a teenager and claims the shot led to impaired mobility that confined her to a wheelchair. Her lawsuit also claims that Merck ( MRK ) marketed the vaccine as safe while concealing knowledge of dangerous side effects. Merck ( MRK ) has denied the claims.

"Merck ( MRK ) remains confident that it will prevail in the Robi litigation based not only on the scientific evidence and defenses that it had presented during plaintiff's own case, but also the additional evidence Merck ( MRK ) would have presented in its defense, which had not even begun when plaintiff's counsel proposed the adjournment," the company said.

"An overwhelming body of scientific evidence, including more than 30 years of research and development along with real world evidence generated by Merck ( MRK ) and by independent investigators, continues to support the safety and efficacy profiles of our HPV vaccines," the company added.